NBP NovaBridge Biosciences
NovaBridge Biosciences (NBP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $79.9K.
Where they traded
Last open-market purchase: April 24, 2026 , by Hagler Mark Arnold .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Dennis Phillip Andrew | Chief Medical Officer | Sell | 8,209 | $0.71 | $5.8K | 173,427 −4.5% of holding | |
| Cao Sean Wuxiong | Chief Bus. Development Officer | Sell | 107,978 | $0.74 | $79.9K | 266,467 −28.8% of holding | |
| Xu Cong Claire | EVP, Clinical Development | Sell | 3,282 | $0.79 | $2.6K | 304,201 −1.1% of holding | |
| Xu Cong Claire | SVP, Clinical Development | Sell | 4,485 | $0.89 | $4.0K | 298,101 −1.5% of holding | |
| Dennis Phillip Andrew | Chief Medical Officer | Sell | 8,494 | $0.66 | $5.6K | 157,941 −5.1% of holding | |
| Xu Cong Claire | SVP, Clinical Development | Sell | 3,494 | $3.94 | $13.8K | 290,154 −1.2% of holding | |
| Cao Sean Wuxiong | See Remarks | Sell | 21,399 | $1.99 | $42.6K | 35,073 −37.9% of holding | |
| Hagler Mark Arnold | See Remarks | Buy | 230,000 | $2.51 | $577.3K | 230,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.